Investigation of the Clinical,Serological and Genetic Factors That Determine Primary Non-response, Loss of Response and Adverse Drug Reactions to Anti-TNF Drugs in Patients With Active Luminal Crohn's Disease

Trial Profile

Investigation of the Clinical,Serological and Genetic Factors That Determine Primary Non-response, Loss of Response and Adverse Drug Reactions to Anti-TNF Drugs in Patients With Active Luminal Crohn's Disease

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Infliximab (Primary) ; Adalimumab
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms PANTS
  • Most Recent Events

    • 20 Feb 2018 New trial record
    • 17 Feb 2018 Results presented in a Celltrion media release.
    • 17 Feb 2018 According to a Celltrion media release, results from this trial were presented at the 13th Congress of the European Crohn's and Colitis Organisation (ECCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top